Fludarabine | Aplastic Anemia & MDS International Foundation


Brand name: 

The U.S. Food and Drug Administration (FDA) approved fludarabine for treating chronic lymphocytic leukemia (CCL). Researchers are studying fludarabine in combination with other medicines for treating bone marrow failure.

Related Clinical Trials

Clinical Trial Status Age Group
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers Recruiting 11 years to 90 years
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Recruiting 1 year to 75 years
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia Recruiting Up to 70 years
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA) Recruiting 3 months and older
LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS) Not yet recruiting 18 years and older
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting 18 years and older
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases Recruiting up to 74 years
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies Recruiting 2 to 35 years
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia Available up to 73 years
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Active, not recruiting up to 75 years
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia Recruiting up to 25 years

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.